- Home
- POWW vs IPHA Comparison
POWW vs IPHA Comparison
Compare POWW & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POWW
- IPHA
- Stock Information
- Founded
- POWW 1990
- IPHA 1999
- Country
- POWW United States
- IPHA France
- Employees
- POWW N/A
- IPHA N/A
- Industry
- POWW Ordnance And Accessories
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- POWW Industrials
- IPHA Health Care
- Exchange
- POWW Nasdaq
- IPHA Nasdaq
- Market Cap
- POWW 157.9M
- IPHA 160.1M
- IPO Year
- POWW N/A
- IPHA 2019
- Fundamental
- Price
- POWW $1.43
- IPHA $1.97
- Analyst Decision
- POWW Hold
- IPHA Strong Buy
- Analyst Count
- POWW 1
- IPHA 1
- Target Price
- POWW $1.50
- IPHA $11.50
- AVG Volume (30 Days)
- POWW 386.9K
- IPHA 28.5K
- Earning Date
- POWW 06-12-2025
- IPHA 03-27-2025
- Dividend Yield
- POWW N/A
- IPHA N/A
- EPS Growth
- POWW N/A
- IPHA N/A
- EPS
- POWW N/A
- IPHA N/A
- Revenue
- POWW $135,498,023.00
- IPHA $20,831,349.00
- Revenue This Year
- POWW $5.67
- IPHA $220.44
- Revenue Next Year
- POWW N/A
- IPHA $81.85
- P/E Ratio
- POWW N/A
- IPHA N/A
- Revenue Growth
- POWW N/A
- IPHA N/A
- 52 Week Low
- POWW $0.95
- IPHA $1.29
- 52 Week High
- POWW $2.86
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- POWW 54.13
- IPHA 53.30
- Support Level
- POWW $1.24
- IPHA $1.81
- Resistance Level
- POWW $1.38
- IPHA $2.00
- Average True Range (ATR)
- POWW 0.08
- IPHA 0.14
- MACD
- POWW 0.01
- IPHA 0.02
- Stochastic Oscillator
- POWW 100.00
- IPHA 53.76
About POWW AMMO Inc.
AMMO Inc is the owner of GunBroker.com, the online marketplace serving the firearms and shooting sports industries, and a vertically integrated producer of high-performance ammunition and components. It engages in the design, manufacture, and market of ammunition products in the Shooting sports industry in the United States. The firm's product segment comprises Ammunition and Marketplace. The Ammunition segment engages in the design, production, and marketing of ammunition and ammunition component products and the marketplace segment consists of the GunBroker.com marketplace. The company generates the majority of its revenue from the Ammunition segment.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.